In this video, Fool health-care analyst David Williamson discusses Discovery Labs (NASDAQ: DSCO), as it struggles with yet another delay to its drug Surfaxin. Shares are down 15% on news that the FDA has requested Surfaxin product specifications and a new analytical chemistry method. It took the company an unbelievable five attempts to finally get this drug approved a year ago. David tells investors when they might expect the delays to end, and what the key things to watch with Discovery Labs will be in the meantime, as the company continues to lose out on sales and burn cash.
Discovering Yet Another Drug Delay
By Dave Williamson
-
Apr 15, 2013 at 6:46PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
This company is king when it comes to drug delays.
Related Articles
Better Buy: Gingko Bioworks vs. Amyris
Have $2,000? 2 Market Crash-Ready Stocks to Buy
Stock Market Plunge: 5 Unstoppable Stocks on Sale to Buy Now and Hold Forever
2 Safe Stocks to Buy in a Bear Market
Tech Stock Sell-Off Got You Scared? Here's a Better Buy.
Motley Fool Returns
Market-beating stocks from our award-winning service.
Stock Advisor Returns
330%
330%
S&P 500 Returns
115%
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.